17 September 2026
Latham Advises GSK on Agreement to Acquire a Potential Best-in-Class Trispecific T Cell-Engager
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Lydia Torne Lead | Latham & Watkins LLP | Partner | Not stated | London |
| Eliot Choy | Latham & Watkins LLP | Counsel | Not stated | Not stated |
| Andrew Wang | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Leah Sauter | Latham & Watkins LLP | Partner | corporate | New York |
| Patrick English | Latham & Watkins LLP | Partner | anti-trust | Washington, D.C. |
| Howard Lam | Latham & Watkins LLP | Partner | finance | Hong Kong |
| Flora Innes | Latham & Watkins LLP | Counsel | finance | Not stated |
| Michelle Wong | Latham & Watkins LLP | Associate | finance | Not stated |
| Benjamin Han | Latham & Watkins LLP | Associate | finance | Not stated |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 750m (US$750 million)
- What the figure measures
- Total transaction value
- Client
- GSKBuy-side
- Counterparties
- Chimagen Biosciences (Sell-side)